NIH launches major lyme disease observation study to uncover hidden clues
NCT ID NCT00028080
First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 10 times
Summary
This study follows 500 people with active Lyme disease to learn more about the infection. Participants receive standard FDA-approved treatments and undergo tests like blood draws and leukapheresis. The goal is to explore biological markers, track clinical outcomes, and understand immune responses—not to test new drugs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could improve understanding of Lyme disease, helping to identify biological markers and better track patient outcomes.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly test new therapies or cures, and results may take years to translate into clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYME DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune cell tracking could sharpen lyme disease diagnosis
- Lyme disease and parenthood: a hidden struggle revealed
- Lyme disease in pregnancy: new study tracks baby brain development
- New blood test aims to spot lyme disease in kids faster and more accurately
- New mRNA vaccine could stop lyme disease in its tracks
- Could a single pill stop lyme disease before it starts?